The anti-Parkinsonian, monoamine oxidase-B inhibitor drug, rasagiline (Azilect®), is primarily metabolized by hepatic cytochrome P450 isoenzyme 1A2-mediated N-dealkylation to form its major metabolite, 1-(R)-aminoindan. The present study was undertaken to further investigate, for the first time, the possible neuroprotective effect of 1-(R)-aminoindan in two rat models of Parkinson's disease, the 6-hydroxydopamine- and lactacystin (a proteasomal inhibitor)-induced nigrostriatal degeneration. 1-(R)-aminoindan reversed behavioral asymmetry and restored striatal catecholamine levels in these two rat models and significantly protected neurons from hydrogen peroxide-induced oxidative stress. These observations indicate that 1-(R)-aminoindan may contribute to the overall neuroprotective activity of its parental compound, rasagiline. Antioxid. Redox Signal. 14, 767–775.
Get full access to this article
View all access options for this article.
References
1.
Abu-RayaS, TabakmanR, BlaugrundE, TrembovlerV, LazaroviciP. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol, 434:109–116. 2002.
2.
Bar-AmO, WeinrebO, AmitT, YoudimMB. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-Parkinsonian drug rasagiline. J Neurochem, 112:1131–1137. 2010.
3.
BindaC, HubalekF, LiM, HerzigY, SterlingJ, EdmondsonDE, MatteviA. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J Med Chem, 48:8148–8154. 2005.
4.
BrotchieGM, JohnstonTH, VisanjiN, PiresP, ThieleS, Fitzer-AttasC, MontezinhoLCP, MørkA, ThomsenC. 1-aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease. Park Rel Dis Supp, 2,S1022007.
5.
FornaiF, LenziP, GesiM, FerrucciM, LazzeriG, CapobiancoL, de BlasiA, BattagliaG, NicolettiF, RuggieriS, PaparelliA. Similarities between methamphetamine toxicity and proteasome inhibition. Ann N Y Acad Sci, 1025:162–170. 2004.
6.
GassenM, LamensdorfI, ArmonyT, FinbergJP, YoudimMB. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J Neural Transm, 110:171–182. 2003.
7.
LazzeriG, LenziP, GesiM, FerrucciM, FulceriF, RuggieriS, BrunoV, FornaiF. In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition. Ann N Y Acad Sci, 1074:174–177. 2006.
8.
McNaughtKS, BjorklundLM, BelizaireR, IsacsonO, JennerP, OlanowCW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport, 13:1437–1441. 2002.
9.
McNaughtKS, OlanowCW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging, 27:530–545. 2006.
10.
MehtaA, ChesseletMF. Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat. Exp Neurol, 193:110–117. 2005.
11.
MillerRL, James-KrackeM, SunGY, SunAY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res, 34:55–65. 2009.
12.
MurphyTH, SchnaarRL, CoyleJT. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J, 4:1624–1633. 1990.
13.
OlanowCW, RascolO, HauserR, FeiginPD, JankovicJ, LangA, LangstonW, MelamedE, PoeweW, StocchiF, TolosaE. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361:1268–1278. 2009.
14.
OlssonM, NikkhahG, BentlageC, BjorklundA. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci, 15:3863–3875. 1995.
15.
OuXM, LuD, JohnsonC, ChenK, YoudimMB, RajkowskaG, ShihJC. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res, 16:148–159. 2009.
ReynoldsGP, ElsworthJD, BlauK, SandlerM, LeesAJ, SternGM. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol, 6:542–544. 1978.
18.
RideoutHJ, StefanisL. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci, 21:223–238. 2002.
19.
ShacharDB, KahanaN, KampelV, WarshawskyA, YoudimMB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology, 46:254–263. 2004.
20.
SmithMP, CassWA. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience, 144:1057–1066. 2007.
21.
SpeiserZ, LevyR, CohenS. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Supplement, 52:287–300. 1998.
22.
SterlingJ, VeinbergA, LernerD, GoldenbergW, LevyR, YoudimM, FinbergJ. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl, 52:301–305. 1998.
23.
TazikS, JohnsonS, LuD, JohnsonC, YoudimMB, StockmeierCA, OuXM. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res, 15:284–290. 2009.
24.
WaldmeierPC. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain)J Neural Transm Suppl, 23:55–72. 1987.
25.
WeinrebO, AmitT, Bar-AmO, YoudimMB. Rasagiline; a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol, 92:330–344. 2010.
26.
WeinrebO, Bar-AmO, AmitT, YoudimMB. The novel cholinesterase- The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact, 175:318–326. 2008.
27.
YoshidaT, YamadaY, YamamotoT, KuroiwaY. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica, 16:129–136. 1986.
28.
YoudimMBH, TiptonKF. Rat striatal monoamine oxidases inhibition by I-deprenyl and rasagiline: its relationship to 2-phenylethylaminenduced stereotypy and parkinson's disease. Parkinsonism Relat Disord, 8:247–253. 2002.
29.
ZhangL, YuH, SunY, LinX, ChenB, TanC, CaoG, WangZ. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol, 564:18–25. 2007.
30.
ZhuW, XieW, PanT, JankovicJ, LiJ, YoudimMB, LeW. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem, 105:1970–1978. 2008.
